|
業務類別
|
Biotechnology |
|
業務概覽
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa. |
| 公司地址
| 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116 |
| 電話號碼
| +1 617 468-4219 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bicara.com |
| 員工數量
| 103 |
| Dr. Claire Mazumdar, M.B.A.,PhD |
Chief Executive Officer and Director |
美元 625.00K |
27/04/2026 |
| Dr. David Raben, M.D. |
Chief Medical Officer |
美元 525.00K |
27/04/2026 |
| Ms. Lara Meisner |
Chief Legal Officer, Compliance Officer and Corporate Secretary |
-- |
27/04/2026 |
| Mr. Ryan Cohlhepp |
Director, President and Chief Operating Officer |
美元 588.00K |
27/04/2026 |
| Mr. Ivan Hyep |
Chief Financial Officer, Treasurer and Principal Accounting Officer |
-- |
27/04/2026 |
|
|
| Ms. Kate Haviland, M.B.A. |
Independent Director |
27/04/2026 |
| Mr. Scott Robertson, M.B.A. |
Independent Director |
27/04/2026 |
| Dr. Claire Mazumdar, M.B.A.,PhD |
Chief Executive Officer and Director |
27/04/2026 |
| Dr. Carolyn Ng, PhD |
Independent Director |
27/04/2026 |
| Dr. Nils Lonberg, PhD |
Independent Director |
27/04/2026 |
| Mr. Ryan Cohlhepp |
Director, President and Chief Operating Officer |
27/04/2026 |
| Dr. Christopher Bowden, M.D. |
Independent Director |
27/04/2026 |
| Ms. Kiran Mazumdar-Shaw |
Independent Director |
27/04/2026 |
| Dr. Michael F. Powell, PhD |
Chairman of the Board |
27/04/2026 |
| Dr. Jake Simson, PhD |
Independent Director |
27/04/2026 |
|
|
|
|
